Para acceder a los documentos con el texto completo, por favor, siga el siguiente enlace:

Patentes, regulación de precios e innovación en la industria farmacéutica
Ortún, Vicente
Universitat Pompeu Fabra. Departament d'Economia i Empresa
The trade-off between property rights/price regulation and innovation depends on countrycharacteristics and drug industry specificities. Access to drugs and innovation can bereconciled by seven ways that, among others, include: public health strengthening in thecountries with the largest access problems (those among the poor with the weakestinstitutions); public and private aid to make attractive R&D on neglected diseases; pricediscrimination with market segmentation; to require patent owners to choose eitherprotection in the rich countries or protection in the poor countries (but not both).Regarding price regulation, after a review of theoretical arguments and empirical evidence,seven strategies to reconcile health and industrial considerations are outlined, including:mitigation of the medical profession dependence on the pharmaceutical industry; considerationof a drug as an input of a production process; split drug authorization from public fundingdecisions; establish an efficiency minimum for all health production inputs; and stop theEuropean R&D hemorrhagia.
Labour, Public, Development and Health Economics
i+d farmacéutico
acceso a medicamentos
regulación de precios
política industrial
política sanitaria
L'accés als continguts d'aquest document queda condicionat a l'acceptació de les condicions d'ús establertes per la següent llicència Creative Commons
Documento de trabajo

Mostrar el registro completo del ítem